Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Zymeworks Inc.NASDAQ: ZYME
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow turns positive
Q3 FY2026 financing cash flow was $334.85M, compared with -$2.45M a year earlier. Trailing-twelve-month financing cash flow was $444.83M.
Context
- Financing cash flow amounted to 17.5% of revenue in FY2025, down 9.3 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $334.85M or moves back toward the trailing-twelve-month quarterly average of $111.21M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (18.56M) USD
- Year-over-year change
- +9.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.56M) | +9.3% |
| FY2024 | 2024-12-31 | (20.45M) | -125.0% |
| FY2023 | 2023-12-31 | 81.85M | -24.6% |
| FY2022 | 2022-12-31 | 108.58M | +1255.4% |
| FY2021 | 2021-12-31 | 8.01M | — |
Financing Cash Flow vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 financing cash flow of $444.83M is the largest of the 11 companies compared; the peer median is $206.21M.
- Its year-over-year change of +5357.5% is the 3rd highest of 10, against a peer median of +403.3%.
- Financing cash flow amounts to 167.2% of revenue for ZYME, versus a peer median of 117.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $444.83M | +5357.5% | — | 167.2% | |
| LTM Sep 2026 | $436.09M | +91.6% | +2614.9% | — | |
| LTM Mar 2026 | $344.93M | +4594.2% | +454.4% | 970.5% | |
| LTM Sep 2026 | $327.45M | +22878.8% | -16.3% | 292364.3% | |
| LTM Mar 2026 | $316.04M | +699.2% | +326.7% | 2659.6% | |
| LTM Aug 2026 | $261.21M | +28.6% | +26.8% | 37.2% | |
| LTM Mar 2026 | $151.21M | +55.9% | — | 191.0% | |
| LTM Mar 2026 | $139.89M | +403.3% | -66.8% | — | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Jun 2026 | $8.3M | -95.9% | +13.0% | 7.9% | |
| LTM Dec 2025 | $0 | — | +210.9% | 0.0% | |
| Peer median (excluding ZYME) | $206.21M | +403.3% | +210.9% | 117.6% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| Deferred Income Tax | (953K) | 1.94M | (757K) | 691K | 945K |
| Stock-Based Compensation | 10.76M | 4.02M | 8.1M | 17.79M | 28.03M |
| Change in Working Capital | 393K | 4.02M | (25.55M) | (30.95M) | 7.5M |
| Accounts Receivables | (266K) | (17.51M) | 13.92M | (36.36M) | 51.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.48M | 26.48M | (44.77M) | 14.34M | (23.65M) |
| Other Working Capital | (15.82M) | (4.96M) | 5.3M | (8.93M) | (20.05M) |
| Other Non-Cash Items | (387K) | (2.21M) | 1.27M | 13.93M | 532K |
| Operating Cash Flow | (192.45M) | 144.11M | (118.3M) | (110.04M) | (33.01M) |
| Capital Expenditures | (13.29M) | (13.13M) | (4.08M) | (3.07M) | (1.52M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.08M) | (40.72M) | (553.25M) | (283.74M) | (196.06M) |
| Sales of Investments | 192.96M | (40.72M) | 350.07M | 325.57M | 225.08M |
| Other Investing Activities | (881K) | 40.72M | (1.6M) | (1.08M) | 0 |
| Investing Cash Flow | 144.6M | (53.85M) | (207.25M) | 38.76M | 26.66M |
| Debt Repayment | (17K) | (14K) | (21K) | (14K) | 0 |
| Common Stock Issued | 0 | 107.53M | 76.1M | 0 | 23.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (30.05M) | (41.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.03M | 1.06M | 5.77M | 9.61M | (181K) |
| Financing Cash Flow | 8.01M | 108.58M | 81.85M | (20.45M) | (18.56M) |
| Effect of Forex Changes | (325K) | 203K | 354K | 286K | (45K) |
| Net Change in Cash | (40.17M) | 199.05M | (243.36M) | (91.45M) | (24.95M) |
| Free Cash Flow | (205.74M) | 130.98M | (122.38M) | (113.11M) | (34.53M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.